Aspire Biopharma holder reports 7.7% ownership stake

Aspire Biopharma Holdings, Inc. shareholder Gary Shirinyan reported his ownership of the company’s common stock.

Rhea-AI Filing Summary

Aspire Biopharma Holdings, Inc. shareholder Gary Shirinyan reported his ownership of the company’s common stock. He beneficially owns 99,900 shares of common stock, representing 7.7% of the outstanding class. He has sole voting power and sole dispositive power over all 99,900 shares, with no shared voting or dispositive authority.

Key Figures

Beneficial ownership: 99,900 shares Percent of class: 7.7% Sole voting power: 99,900 shares +3 more

6 metrics

Beneficial ownership 99,900 shares Common stock beneficially owned by Gary Shirinyan

Percent of class 7.7% Percentage of Aspire Biopharma common stock class owned

Sole voting power 99,900 shares Shares over which he has sole power to vote or direct the vote

Shared voting power 0 shares Shares over which he has shared power to vote or direct the vote

Sole dispositive power 99,900 shares Shares over which he has sole power to dispose or direct disposition

Shared dispositive power 0 shares Shares over which he has shared power to dispose or direct disposition

Key Terms

Schedule 13G, beneficially owned, sole voting power, sole dispositive power

4 terms

Schedule 13G regulatory

"submitted a <b>Schedule 13G</b> reporting his beneficial ownership"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

beneficially owned financial

"He beneficially owns <b>99,900 shares</b> of common stock"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power financial

"He has <b>sole voting power</b> and sole dispositive power over all 99,900 shares"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"and <b>sole dispositive power</b> over all 99,900 shares"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of Aspire Biopharma (ASBP) does Gary Shirinyan own?

Gary Shirinyan beneficially owns 7.7% of Aspire Biopharma Holdings, Inc.’s common stock. This ownership is based on 99,900 shares reported as beneficially owned, as disclosed in the Schedule 13G filing.

How many Aspire Biopharma (ASBP) shares does Gary Shirinyan control?

Gary Shirinyan controls 99,900 shares of Aspire Biopharma common stock. He has sole power to vote and dispose of all these shares, with no shared voting or dispositive authority reported.

What type of filing did Gary Shirinyan submit for Aspire Biopharma (ASBP)?

Gary Shirinyan submitted a Schedule 13G reporting his beneficial ownership in Aspire Biopharma Holdings, Inc. This filing discloses passive ownership of 99,900 shares, or 7.7% of the company’s common stock.

Does Gary Shirinyan share voting power over Aspire Biopharma (ASBP) shares?

No. The filing states sole voting power over 99,900 shares and shared voting power of 0. He alone can vote or direct the vote for the reported Aspire Biopharma shares.

Does Gary Shirinyan have sole dispositive power over his Aspire Biopharma (ASBP) holding?

Yes. The Schedule 13G reports sole dispositive power over 99,900 shares and shared dispositive power of 0, meaning he alone can decide to sell or otherwise dispose of these shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/10/2026 - 08:30 PM Accepted by SEC EDGAR 08/10/2026 - 08:30 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Aspire Biopharma Holdings, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

738920305

(CUSIP Number)

06/17/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 738920305

1

Names of Reporting Persons

GARY SHIRINYAN

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 99,900.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 99,900.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

99,900.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.7 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Aspire Biopharma Holdings, Inc.
(b)	Address of issuer's principal executive offices: 23150 FASHION DRIVE, SUITE 232, ESTERO, FL, 33928
Item 2.
(a)	Name of person filing: GARY SHIRINYAN
(b)	Address or principal business office or, if none, residence: 5340 NATICK AVE SHERMAN OAKS CA 91411
(c)	Citizenship: United States
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP Number(s): 738920305
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 99,900
(b)	Percent of class: 7.7%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 99,900
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 99,900
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

GARY SHIRINYAN

Signature:	/s/ GARY SHIRINYAN
Name/Title:	GARY SHIRINYAN
Date:	08/10/2026